Cross Q&A: Balancing Progression and Lines of Therapy at Myeloma Relapse
Expert insights into tailoring treatment for biochemical relapse in multiple myeloma patients, considering disease progression and the impact of various therapy lines on treatment decisions.
Cross Q&A: Navigating Biochemical Relapse and MRD Resurgence in Multiple Myeloma
An insightful discussion among specialists about the challenges of treating biochemical relapse and MRD resurgence in multiple myeloma patients, exploring nuanced considerations, patient collaboration, and the evolving landscape of treatment strategies.
Cross Q&A: Dosing Ponatinib in CML to Balance Efficacy and Cardiovascular Safety
Experts discuss dosing strategies and risk factors for arterial occlusive events in ponatinib treatment for chronic myeloid leukemia, emphasizing the importance of balancing disease control and patient safety.
Dosing Strategies and Disease Control With Ponatinib: The OPTIC Study
An expert explores findings of the OPTIC study, revealing optimal dosing strategies for ponatinib in CML treatment, including insights into dose reduction and patient response based on T315I mutation status.
Biochemical and Clinical Progression: The Two Faces of Relapsed MM
Andrew Cowan, MD, discusses the complexities of relapsed multiple myeloma, distinguishing between biochemical and clinical progression, analyzing survival data, and raising questions about optimal treatment strategies.
Team Introductions: MM Experts From the Fred Hutchinson Cancer Center and City of Hope
An overview of the program agenda and introduction of expert panelists from the Fred Hutchinson Cancer Center and City of Hope teams.
Optimizing Ponatinib in CML: Understanding AOEs in the PACE Trial
A retrospective analysis of arterial occlusive events in the PACE trial, shedding light on risk factors and management strategies for ponatinib treatment in CML patients.
Team Introductions: CML Experts From the Fred Hutchinson Cancer Center and City of Hope
Reflecting on Unmet Needs in Multiple Myeloma After IMS 2022
Closing out their discussion, the panel highlights unmet needs in multiple myeloma that clinicians and patients still face.
Sequencing Therapies in Patients with R/R MM
Drs Cowan and Anderson review whether older agents such as isa-based regimens still have a place in R/R MM treatment after the introduction of bispecific agents and CAR-T therapy.
Choosing a Bispecific Antibody for Treatment of R/R MM After Prior BCMA Therapy
Dr Silbermann continues her discussion of BCMA-targeting agents with a look at data on the use of bispecific agents for R/R MM treatment after a patient has already received a BCMA therapy.
CAR-T Therapy in R/R MM Treatment
Key opinion leaders compare the overall benefits of CAR-T therapy and share some advice for managing the toxicities of CAR-T therapy as a patient transitions back to their local doctor.
Available Treatment Options for Relapsed/Refractory Multiple Myeloma
Drs Sidana and Silbermann describe the currently available treatment options for early- and late-relapse MM, and how to select an appropriate regimen.
Bispecific Antibodies in the Treatment of R/R MM
An explanation of the mechanism of action of bispecific antibodies and their use in relapsed/refractory multiple myeloma treatment.
Role of Triplet Therapy in Frail Patients with Transplant-Ineligible NDMM
Dr Caitlin Costello discusses how she adapts treatment to patients with transplant-ineligible NDMM based on fitness level, and why some patients receive doublet therapy.
Maintenance Therapy in Transplant-Ineligible NDMM
Experts explain their approaches to maintenance therapy for patients with transplant-ineligible NDMM and when therapy should be reduced.
Transplant-Ineligible Multiple Myeloma: The MAIA and SWOG 0777 Trials
Dr Larry Anderson summarizes the study design and updated data of the MAIA trial, and Dr Rebecca Silbermann compares it against the SWOG 0777 trial.
Transplant-Ineligible Multiple Myeloma: The ENDURANCE Study
Andrew Cowan, MD, presents the results of the ENDURANCE study comparing two triplet regimens in transplant-ineligible MM.
Factors to Consider for Frontline Treatment of Transplant-Ineligible MM
Caitlin Costello, MD, describes how to determine if a patient with MM is transplant-ineligible, and some factors to take into consideration when choosing a treatment regimen.
Treating Patients with High-Risk NDMM
The panel explains their opinions on induction therapy approaches for high-risk and standard-risk patients with NDMM.
Duration of Therapy and Maintenance Treatment in Transplant-Eligible NDMM
Dr Andrew Cowan describes how the appropriate duration of therapy for patients with transplant-eligible multiple myeloma, and Dr Caitlin Costello discusses her approach to maintenance therapy.
Determining the Right Patients with NDMM for Autologous Stem Cell Transplant
Larry Anderson, MD, explains the study design and outcomes of the DETERMINATION study, and sparks a discussion on which patients with NDMM should receive stem cell transplants.
Minimal Residual Disease-Response Adapted Therapy in Transplant-Eligible NDMM
Dr Rebecca Silbermann discusses the results of studies evaluating MRD-response adapted therapy in patients with transplant-eligible NDMM.
Choosing the Appropriate Induction Regimen in Transplant-Eligible NDMM
Surbhi Sidana, MD, and Caitlin Costello, MD, introduce the updated evidence regarding induction regimens for patients with transplant-eligible NDMM and how to select the appropriate induction regimen in this population.
Andrew J. Cowan, MD, Discusses the Phase I Clinical Trial of GSI and BCMA CAR T-Cells
The expert explained the rationale for the phase I first-in-human clinical trial evaluating the combination of a gamma-secretase inhibitor and B-cell maturation antigen CAR T-cells in patients with heavily pretreated multiple myeloma.
2 Clarke Drive Cranbury, NJ 08512